Table 2

PCV13 effectiveness estimates against all episodes of confirmed pCAP and CAP due to vaccine serotypes in adults by vaccination status and the presence of underlying conditions

Cases vaccinated/
unvaccinated
Controls vaccinated/
unvaccinated*
Vaccine effectiveness (%)95% CI
pCAP (any strain)5/5415/108†33.2−106.6% to 82%
VT-CAP3/3617/126‡38.1−131.9% to 89%
VT-CAP in the age group at higher vaccine uptake (65–75 years)2/148/32‡42.3−244.1% to 94.7%
pCAP in patients with ≥1 comorbid disorder5/4615/90†34.6−104.6% to 82.5%
VT-CAP in patients with ≥1 comorbid disorder3/3117/105‡40.1−127.5% to 89.4%
pCAP in patients naïve to PPSV23 or vaccinated with PPSV23 ≥5 years prior to enrolment5/3414/69†27.3−136.5% to 81.5%
VT-CAP in patients naïve to PPSV23 or vaccinated with PPSV23 ≥5 years prior to enrolment3/1916/84‡17−234.7% to 85.9%
  • *Vaccine data were missing for four controls.

  • †Controls were patients  with an episode of non- pneumococcal pneumonia.

  • ‡Controls were patients with NVT pneumococcal CAP, non-typeable isolates or non- pneumococcal pneumonia. 

  • CAP, community-acquired pneumonia; NVT, non-vaccine-type; pCAP, pneumococcal community-acquired pneumonia; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; VT, vaccine-type.